SCHEMBL1856441

SCHEMBL1856441

Cc1ccc(NS(=O)(=O)c2cccc(CCCC(CCCc3ccccc3)C(=O)O)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 3/20 0.53
ALDH1A1 P00352 3/20 0.51
HDAC1 Q13547 4/20 0.49
HDAC8 Q9BY41 4/20 0.49
PGR P06401 2/20 0.49
NAMPT P43490 1/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
GAA P10253 1/20 0.48
LIMK2 P53671 1/20 0.47
AR P10275 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
HDAC4 P56524 2/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
HDAC3 O15379 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8037792 0.98 HTR6 (0.51) HTR6ALDH1A1HDAC1HDAC8PGR
SCHEMBL8039484 0.91 HTR6 (0.58) HTR6HDAC1HDAC8NAMPTMEN1
SCHEMBL1855593 0.88 HTR6 (0.54) HTR6ALDH1A1MEN1KMT2AGAA
SCHEMBL12630239 0.84 NAMPT (0.45) HTR6ALDH1A1HDAC1HDAC8NAMPT
SCHEMBL1861394 0.84 HTR6 (0.44) HTR6ALDH1A1HDAC1HDAC8PGR
SCHEMBL3467103 0.84 MMP13 (0.46) ALDH1A1HDAC8PGRNAMPT
SCHEMBL1857972 0.84 NPC1 (0.49) HTR6ALDH1A1HDAC1HDAC8NAMPT
SCHEMBL1856429 0.83 POLB (0.51) HTR6ALDH1A1
SCHEMBL1860527 0.80 HDAC1 (0.54) HTR6HDAC1HDAC8MEN1KMT2A
SCHEMBL1855764 0.80 MMP2 (0.46) HTR6ALDH1A1HDAC1HDAC8PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110105544-A1 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS, S.L. (ES) 2011-05-05 US claimed
WO-2009080722-A2 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS, S.L. (ES) 2009-07-02 WO claimed
US-20110105544-A1 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS, S.L. (ES) 2011-05-05 US disclosed
US-20110105544-A1 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS, S.L. (ES) 2011-05-05 US disclosed
US-20110105544-A1 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS, S.L. (ES) 2011-05-05 US disclosed
WO-2009080722-A2 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS, S.L. (ES) 2009-07-02 WO disclosed
WO-2009080722-A2 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS, S.L. (ES) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105544-A1 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AKR1C3, TPD52L2, HCCS HTR6 3261/4885ALDH1A1 198/4885HDAC1 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.